Top

Published in:

01-04-2012 | Original Article

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

Authors: Zhi-Qiang Ning, Zhi-Bin Li, Michael J. Newman, Song Shan, Xin-Hao Wang, De-Si Pan, Jin Zhang, Mei Dong, Xin Du, Xian-Ping Lu

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2012

Abstract

Purpose

Chidamide (CS055/HBI-8000) is a new histone deacetylase (HDAC) inhibitor of the benzamide class currently under clinical development in cancer indications. This study reports the in vitro and in vivo antitumor characteristics of the compound.

Methods

Selectivity and potency of chidamide in inhibition of HDAC isotypes were analyzed by using a panel of human recombinant HDAC proteins. Tumor cell lines either in culture or inoculated in nude mice were used for the evaluation of the compound’s antitumor activity. To investigate the immune cell-mediated antitumor effect, isolated peripheral blood mononuclear cells from healthy donors were treated with chidamide, and cytotoxicity and expression of relevant surface proteins were analyzed. Microarray gene expression studies were performed on peripheral white blood cells from two T-cell lymphoma patients treated with chidamide.

Results

Chidamide was found to be a low nanomolar inhibitor of HDAC1, 2, 3, and 10, the HDAC isotypes well documented to be associated with the malignant phenotype. Significant and broad spectrum in vitro and in vivo antitumor activity, including a wide therapeutic index, was observed. Chidamide was also shown to enhance the cytotoxic effect of human peripheral mononuclear cells ex vivo on K562 target cells, accompanied by the upregulation of proteins involved in NK cell functions. Furthermore, the expression of a number of genes involved in immune cell-mediated antitumor activity was observed to be upregulated in peripheral white blood cells from two T-cell lymphoma patients who responded to chidamide administration.

Conclusions

The results presented in this study provide evidence that chidamide has potential applicability for the treatment of a variety of tumor types, either as a single agent or in combination therapies.

Available only for authorised users

Khan AU, Krishnamurthy S (2005) Histone modifications as key regulators of transcription. Front Biosci 10:866–872PubMedCrossRef

Graham JS, Kaye SB, Brown R (2009) The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer 45:1129–1136PubMedCrossRef

Inoue S, Mai A, Dyer MJ, Cohen GM (2006) Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumour necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 66:6785–6792PubMedCrossRef

Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, Basaki Y, Ono M, Kuwano M, Tanaka M, Tsuneyoshi M (2007) Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 18:769–774PubMed

Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, Kristiansen G (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98:604–610PubMedCrossRef

Park JH, Kim SH, Choi MC, Lee J, Oh DY, Im SA, Bang YJ, Kim TY (2008) Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem Biophys Res Commun 368:318–322PubMedCrossRef

Paris M, Porcelloni M, Binaschi M, Fattori D (2008) Histone deacetylase inhibitors: from bench to clinic. J Med Chem 51:1505–1529PubMedCrossRef

Noureen N, Rashid H, Kalsoom S (2010) Identification of type-specific anticancer histone deacetylase inhibitors: road to success. Cancer Chemother Pharmacol 66(4):625–633PubMedCrossRef

FDA (2006) US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Oncology Drug Products (OODP). Approval letter for ZOLINZA^™, NDA 21-991, Merck and Co. Inc. 6 Oct 2006

10.

FDA (2009) US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Oncology Drug Products (OODP). Approval letter for ISTODAX, NDA 022393, Gloucester Pharmaceuticals. 5 Nov 2009

11.

FDA (2011) US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Oncology Drug Products (OODP). Approval letter for ISTODAX, NDA 022393/S-004, Celgene Corporation. 16 Jun 2011

12.

Xie AH, Li BY, Liao CZ, Li ZB, Lu XP, Shi LM, Zhou JJ (2004) Docking study of HDAC: implication for benzamide inhibitors binding mode. Acta Phys-Chim Sin 20:569–572

13.

Xie AH, Liao CZ, Li ZB, Ning ZQ, Hu W, Lu XP, Shi LM, Zhou J (2004) Quantitative structure-activity relationship study of histone deacetylase inhibitors. Curr Med Chem Anticancer Agents 4:273–299PubMedCrossRef

14.

Yin ZH, Wu ZW, Lan YK, Liao CZ, Shan S, Li ZL, Ning ZQ, Lu XP, Li ZB (2004) Synthesis of chidamide, a new histone deacetylase (HDAC) inhibitor. Chin J New Drugs 13:536–538

15.

Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O (1999) A synthetic inhibitor of histone deacetylase, MS-27–275, with marked in vivo antitumor activity against human tumors. PNAS 96:4592–4597PubMedCrossRef

16.

Hess-Stumpp H, Bracker TU, Henderson D, Politz O (2007) MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Int J Biochem Cell Biol 39:1388–1405PubMedCrossRef

17.

Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF, Gillespie J, Wang JJ, Ste-Croix H, Rahil J, Lefebvre S, Moradei O, Delorme D, Macleod AR, Besterman JM, Li Z (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumour activity in vitro and in vivo. Mol Cancer Ther 7:759–768PubMedCrossRef

18.

Park BL, Kim YJ, Cheong HS, Lee SO, Han CS, Yoon JH, Park JH, Chang HS, Park CS, Lee HS, Shin HD (2007) HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients. Biochem Biophys Res Commun 363:776–781PubMedCrossRef

19.

Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51PubMedCrossRef

20.

Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, Ismail S, Stevens C, Meyn RE (2005) Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11:4912–4922PubMedCrossRef

21.

Qiang L, Xiao H, Campos EI, Ho VC, Li G (2005) Development of a PAN-specific, affinity-purified antiacetylated lysine antibody for detection, identification, isolation, and intracellular localization of acetylated protein. J Immunoass Immunochem 26:13–23CrossRef

22.

Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T, Sanders K (2007) Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 121:1138–1148PubMedCrossRef

23.

Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409:581–589PubMedCrossRef

24.

Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N (2005) Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 65:11136–11145PubMedCrossRef

25.

Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR (2005) Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65:6321–6329PubMedCrossRef

Title: Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
Authors: Zhi-Qiang Ning
Zhi-Bin Li
Michael J. Newman
Song Shan
Xin-Hao Wang
De-Si Pan
Jin Zhang
Mei Dong
Xin Du
Xian-Ping Lu
Publication date: 01-04-2012
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2012
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-011-1766-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2012

Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib

A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors

Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity

Keynote webinar | Spotlight on antibody–drug conjugates in cancer